Life sciences cloud software provider Veeva Systems (NYSE: VEEV) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 17.6% year on year to $928 million. Guidance for next quarter’s revenue was better than expected at $933.5 million at the midpoint, 1.5% above analysts’ estimates. Its non-GAAP profit of $2.35 per share was 5.8% above analysts’ consensus estimates.
Is now the time to buy VEEV? Find out in our full research report (it’s free for active Edge members).
Veeva Systems (VEEV) Q2 CY2026 Highlights:
- Revenue: $928 million vs analyst estimates of $905.3 million (17.6% year-on-year growth, 2.5% beat)
- Adjusted EPS: $2.35 vs analyst estimates of $2.22 (5.8% beat)
- Adjusted Operating Income: $415.9 million vs analyst estimates of $394.8 million (44.8% margin, 5.3% beat)
- The company lifted its revenue guidance for the full year to $3.68 billion at the midpoint from $3.64 billion, a 1.2% increase
- Management raised its full-year Adjusted EPS guidance to $9.21 at the midpoint, a 1.8% increase
- Operating Margin: 29.6%, up from 24.8% in the same quarter last year
- Billings: $760.9 million at quarter end, up 17.1% year on year
- Market Capitalization: $39.78 billion
StockStory’s Take
Veeva Systems’ second quarter was marked by strong execution across its core business lines, particularly in commercial cloud and emerging AI-powered offerings. The company’s outperformance was driven by robust demand for its CRM solutions and rapid adoption of its new Falcon AI product, which management described as a key priority for customers seeking efficiency and compliance gains. CEO Peter Gassner highlighted, “It was our best CRM quarter ever. We also are accelerating rapidly in AI overall and especially with Veeva Falcon.” Management also emphasized ongoing customer momentum in data and consulting, pointing to broad-based strength across segments.
Looking ahead, Veeva Systems is positioning its AI initiatives, particularly the Falcon platform, as central to future growth. Management believes that increased customer interest in agentic labor (a term for AI-driven automated workflows) and the evolution of the company’s pricing strategy will be significant in scaling adoption. CFO Brian Van Wagener noted that investments in Falcon and other early-stage products will be paced to revenue growth and factored into profitability targets, while CEO Gassner stated, “AI is enabling the next big chapter for Veeva and the industry.” The company is also focused on win-back opportunities in CRM and continued expansion of its R&D cloud suite.
Key Insights from Management’s Remarks
Management attributed second quarter momentum to accelerating AI product adoption, strong CRM execution, and a healthy funding environment for biopharma customers.
-
AI-driven product traction: The Falcon platform, which enables automated workflows (“agentic labor”), generated strong customer interest as a priority solution for cost savings and compliance. CEO Peter Gassner explained that Falcon’s implementation is less complex than previous products, shortening deployment cycles and increasing its appeal to early adopters.
-
Broad-based commercial growth: The commercial segment saw double-digit subscription growth, with continued strength in CRM, content, data, and Crossix. CFO Brian Van Wagener pointed out that “Crossix continues to be a strong performer with a lot of headroom for growth,” and commercial wins were spread across multiple product lines, not reliant on any single area.
-
R&D cloud product evolution: The company is transitioning from legacy products like eTMF and CTMS to newer platforms such as EDC, eCOA, Safety, and LIMS. Van Wagener described this as a “changing of the guards,” with the newer products positioned for long-term growth but currently in earlier stages of adoption.
-
Competitive CRM environment: Veeva won two new top 20 biopharma customers for Vault CRM this quarter and sees opportunities to win back customers that have selected alternative platforms. Management cited project delays at competitors as a factor increasing Veeva’s attractiveness.
-
Strategic M&A and partnerships: Recent acquisitions, such as Copli, have added AI talent and capabilities to Veeva’s platform. The partnership with IQVIA has improved customer experience and industry collaboration, with Gassner calling it “probably the best thing that happened to our company 12 months ago.”
Drivers of Future Performance
Management expects AI-powered solutions, CRM win-backs, and continued R&D cloud expansion to drive performance, while monitoring investment levels and evolving pricing strategies.
-
AI adoption and scaling: The Falcon platform and application agents are expected to be major growth engines as customers increasingly seek out AI-enabled solutions for compliance and cost reduction. Management noted that Falcon’s faster deployment and predictable pricing model are resonating, though emphasized the need for continued product development and regulatory readiness.
-
CRM market dynamics: Veeva aims to maintain over 70% share in the life sciences CRM market, leveraging recent Vault CRM wins and focusing on converting customers who have faced challenges with alternative platforms. Management is optimistic about further win-backs as customer projects with competitors experience delays or complications.
-
R&D cloud product mix shift: As legacy R&D products plateau, growth is expected to come from newer platforms such as EDC, eCOA, Safety, and LIMS. These products are still early in their adoption curve but are viewed as key to the company’s long-term trajectory. The company will continue to balance investments in these areas against overall profitability targets.
Catalysts in Upcoming Quarters
Looking ahead, our analysts will be closely monitoring (1) the pace of adoption and go-live milestones for the Falcon platform, (2) progress in winning back top 20 CRM customers and converting competitive opportunities, and (3) advancements in newer R&D cloud products like EDC and LIMS. Execution on AI integration, pricing strategy refinement, and the impact of recent acquisitions will also be crucial markers of Veeva’s ability to sustain momentum.
Veeva Systems currently trades at $291.07, up from $244.72 just before the earnings. Is there an opportunity in the stock? See for yourself in our full research report (it’s free).
Stocks That Trumped Tariffs
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.
